Think your FDA 510(k) is a fast track to a European CE Mark? This episode uncovers the critical gaps between the two regulatory systems. We explore the fundamental differences in philosophy, from the FDA's "substantial equivalence" model to the EU MDR's lifecycle approach, and detail the extra work required in quality management, clinical evidence, technical documentation, and post-market surveillance to achieve compliance in Europe. Key Questions: • Is a 510(k) clearance a shortcut to getting an EU MDR CE Mark? • How do the Quality Management System (QMS) requirements for the FDA and EU differ? • Why isn't the data for my 510(k) enough for a European Clinical Evaluation Report (CER)? • What are the General Safety and Performance Requirements (GSPRs) and why are they crucial for my EU Technical File? • How does the EU's proactive Post-Market Surveillance (PMS) system compare to the FDA's requirements? • What is a Notified Body, and why is their pre-market audit essential for European market access? • What is a Periodic Safety Update Report (PSUR) and will my device require one? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.